Business / Finance

RSS

FTC terms Omnicare's proposed acquisition of PharMerica illegal

The Federal Trade Commission issued a complaint to block Omnicare, Inc.'s hostile acquisition of rival long-term care pharmacy provider PharMerica Corporation, alleging that the combination of the two largest U.S. long-term care pharmacies would harm competition and enable Omnicare to raise the price of drugs for Medicare Part D consumers and others.

30 Jan 2012

Proposed Express Scripts-Medco merger endangers over 2,400 jobs in New Jersey

New Jersey would lose over 2,400 jobs, local economies would suffer and patients may be denied their choice of pharmacy if the proposed mega-merger of two prescription drug middlemen goes through, the National Community Pharmacists Association (NCPA) said today.

30 Jan 2012

Checkpoint Surgical completes $1.7M Series B investment round

Neurodevice firm Checkpoint Surgical completed a $1.7 million Series B investment round led by the NDI Healthcare Fund in December 2011, and secured non-dilutive funding of over $1.3 million, including a $1.065 million Innovation Ohio loan and a $245,000 federal grant.

30 Jan 2012

Bionovo announces voluntary decision to delist from NASDAQ

Bionovo, Inc., today announced that on January 26, 2012, its Board of Directors decided to seek a voluntary delisting from the NASDAQ Capital Market.

30 Jan 2012

Medtronic signs exclusive distribution agreement with Miami Instruments

Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.

From Medtronic 30 Jan 2012

IDEXX fourth quarter revenues increase 8% to $307.2 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.

27 Jan 2012

Amgen enters definitive merger agreement to acquire Micromet

Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

27 Jan 2012

drchrono closes $2.8 million round of funding

drchrono, the company that is transforming the focus of healthcare from the enterprise to the provider, today announced it has closed a $2.8 million round of funding led by Yuri Milner and featuring new investors that share a legacy of innovation and business transformation.

27 Jan 2012

Celgene signs definitive merger agreement to acquire Avila

Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.

26 Jan 2012

St. Jude Medical fourth quarter net sales increase 4% to $1.407B

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and year ended December 31, 2011.

25 Jan 2012

Meridian Bioscience first quarter net sales increase 8% to $40.3 million

Meridian Bioscience, Inc., Cincinnati, Ohio today: reported first quarter net sales of $40.3 million, an increase of 8% from the same period of the prior fiscal year.

25 Jan 2012

Prosensa secures €23M in new equity financing

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.

25 Jan 2012

Roche proposes to acquire Illumina for $44.50 per share

Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

From Roche Sequencing and Life Science 24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

OSI Systems' second quarter revenues increase 11% to $188 million

OSI Systems, Inc., a vertically integrated provider of solutions in Security, Healthcare, and specialized electronics, today announced financial results for the second quarter ended December 31, 2011.

24 Jan 2012

Aquilent awarded new IT contracts by the HHS

Aquilent, the recognized leading provider of Web-based solutions shaping the next generation of technology for the federal government, today announced it has been awarded more than a dozen new contracts within the past several months supporting numerous operating divisions and programs within the U.S. Department of Health and Human Services (HHS).

24 Jan 2012

UCSD receives approval to acquire NVCI

UC San Diego Health System has received approval to acquire the Nevada Cancer Institute (NVCI), the official cancer institute of the state of Nevada, as an affiliate health care provider. The expansion represents a partnership between California and Nevada in offering lifesaving cancer care to patients through expert diagnosis, novel treatments and clinical trials.

24 Jan 2012

Fitbit raises $12 Million in Series C funding

Fitbit, the market leader in the digital health and fitness device category and maker of the popular Fitbit Ultra Wireless Activity and Sleep Tracker, today announced it raised $12 Million in Series C funding from existing investors: Foundry Group, True Ventures, SoftTech VC and Felicis Ventures. The capital will be used to further accelerate the company's strong growth trajectory.

24 Jan 2012

Pernix obtains marketing rights to new gastroenterology product in the U.S.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease.

24 Jan 2012

Watson announces acquisition of Ascent Pharmahealth

Watson Pharmaceuticals, Inc. announced that it has acquired Ascent Pharmahealth Ltd, the Australia and Southeast Asia generic pharmaceutical business of Strides Arcolab Ltd, for AU$375 million in cash.

24 Jan 2012